BioSynthetics
Zurich, Switzerland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $260M
Overview
Synthetic biology firm engineering novel proteins and pathways for metabolic diseases and industrial applications.
Metabolic
Technology Platform
An integrated synthetic biology platform combining computational protein design and automated host engineering to create novel therapeutic enzymes and biosynthetic pathways.
Funding History
1Total raised:$260M
IPO$260M
Opportunities
Potential to create best-in-class enzyme therapies for rare diseases and establish a leading industrial enzyme design partnership business.
Risk Factors
Clinical risk of immunogenicity against novel synthetic enzymes and competition from gene therapy approaches for metabolic disorders.
Competitive Landscape
Faces competition from established enzyme replacement therapy companies like Sanofi and BioMarin, but aims to compete on superior protein engineering and design.